Inhibikase Q1 2026 net loss $16.4M; first patient enrolled in Phase 3 PAH study IMPROVE-PAH

Inhibikase Therapeutics, Inc.

• Net loss $16.4M ($0.10 EPS) vs $13.7M ($0.15) in Q1 2025; cash & equivalents $170.4M as of Mar 31, 2026.
• First patient enrolled in registrational Phase 3 IMPROVE-PAH study for IKT-001 in PAH; EMA approved 12 EU countries, total 16 countries.
• R&D expenses $10.8M (incl. one-time non-cash $7.4M from CorHepta acquisition in prior year); SG&A $7.4M.
• Upcoming presentations at ATS May 17 and 20, 2026 on safety/tolerability/PK and preclinical efficacy of IKT-001.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.